Optimizing the diagnosis and management of ductal prostate cancer-Reference-Cited by-同舟云学术

Optimizing the diagnosis and management of ductal prostate cancer

Published:2021-04-06 Issue:6 Volume:18 Page:337-358
ISSN:1759-4812
Container-title:Nature Reviews Urology
language:en
Short-container-title:Nat Rev Urol

Author:

Ranasinghe Weranja^ORCID,Shapiro Daniel D.,Zhang Miao,Bathala Tharakeswara,Navone Nora,Thompson Timothy C.^ORCID,Broom Bradley,Aparicio Ana,Tu Shi-Ming,Tang Chad,Davis John W.^ORCID,Pisters Louis,Chapin Brian F.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://www.nature.com/articles/s41585-021-00447-3.pdf

Reference139 articles.

1. Knipper, S. et al. Contemporary comparison of clinicopathologic characteristics and survival outcomes of prostate ductal carcinoma and acinar adenocarcinoma: a population-based study. Clin. Genitourin. Cancer 17, 231–237.e2 (2019).

2. Samaratunga, H., Duffy, D., Yaxley, J. & Delahunt, B. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum. Pathol. 41, 281–285 (2010).

3. Vinceneux, A. et al. Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate 77, 1242–1250 (2017).

4. Jang, W. S. et al. Prognostic significance of the proportion of ductal component in ductal adenocarcinoma of the prostate. J. Urol. 197, 1048–1053 (2017).

5. Harkin, T. et al. High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU Int. 124, 907–909 (2019).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine;Expert Review of Vaccines;2024-09-02

2. Prostate ductal adenocarcinoma exhibiting a late recurrence in the anterior urethra 13 years post-total prostatectomy: a case report;Journal of Medical Case Reports;2024-08-17

3. 68Ga-PSMA PET/CT and 18F-FDG PET/CT in the diagnosis of prostatic ductal cancer;Urologic Oncology: Seminars and Original Investigations;2024-08

4. Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate;World Journal of Urology;2024-07-11

5. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management;Urologic Oncology: Seminars and Original Investigations;2024-05